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for the Segeberg-Krozingen TAVI Registry
Bad Segeberg and Bad Krozingen, GermanyObjectives This study sought to assess aortic regurgitation (AR) after transcatheter aortic valve
implantation (TAVI) with the self-expandable Medtronic CoreValve (MCV) (Medtronic Inc., Minneapolis,
Minnesota) versus balloon-expandable Edwards Sapien XT valve (ESV) (Edwards Lifesciences, Irvine,
California).
Background AR after TAVI has been associated with poor survival, but limited data exist comparing
MCV with ESV.
Methods We pooled the prospective TAVI databases of 2 German centers. The primary endpoint was
more-than-mild post-TAVI AR assessed by echocardiography. We also assessed device success and
survival within 1 year. Endpoints were adjudicated according to the Valve Academic Research
Consortium criteria and analyzed by unadjusted and propensity-score–adjusted models.
Results A total of 394 patients were included, 276 treated with MCV and 118 with ESV. More-
than-mild AR was signiﬁcantly higher with MCV than with ESV (12.7% vs. 2.6%, p ¼ 0.002). This
difference remained signiﬁcant after propensity adjustment (adjusted odds ratio [OR]: 4.59, 95%
conﬁdence interval [CI]: 1.03 to 20.44). The occurrence of any degree of AR was also higher with MCV
(71.6% vs. 56.9%, p ¼ 0.004). Device success was mainly inﬂuenced by the occurrence of AR and was
consequently higher with ESV (95.8% vs. 86.6%, p ¼ 0.007), but this was not signiﬁcant after propensity
adjustment (adjusted OR: 0.34, 95% CI: 0.11 to 1.03, p ¼ 0.06). At 1 year, survival was comparable
between both valve types (83.8% MCV vs. 88.2% ESV, p ¼ 0.42), but was signiﬁcantly worse in patients
with more-than-mild AR (69.8% vs. 87.4%, p ¼ 0.004) and in those with device failure (65.6% vs. 87.4%,
p < 0.001).
Conclusions More-than-mild AR after TAVI was more frequent with MCV than with ESV. This ﬁnding
deserves consideration, as more-than-mild AR was associated with higher mortality at 1 year.
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285Transcatheter aortic valve implantation (TAVI) is a new
technique with a growing impact on the treatment of elderly
and high-risk patients with severe aortic stenosis. Although
a variety of transcatheter valves are currently in the pipeline,
only the balloon-expandable Edwards Sapien valve
(Edwards Lifesciences, Irvine, California) has been approved
in the Unites States, whereas both the Edwards valve and
the self-expandable Medtronic CoreValve (Medtronic Inc.,
Minneapolis, Minnesota) are commercially used in Europe.
Both valves have been reported to have excellent ﬂow
characteristics (1,2), but each has speciﬁc features and aortic
anatomic requirements.See page 293
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and Acronyms
AR = aortic regurgitation
AUC = area under the curve
CI = conﬁdence interval
CT = computed tomography
ESV = Edwards Sapien XT
valve
LVOT = left ventricular
outﬂow tract
MCV = Medtronic CoreValve
OR = odds ratio
TAVI = transcatheter aortic
valve implantation
TEE = transesophageal
echocardiography
VARC = Valve Academic
Research ConsortiumAccumulating data have indicated promising results con-
cerning procedural success, quality of life improvement,
and short- and long-term outcomes with both valves (1–4).
Nevertheless, among the clinically-relevant limitations of
TAVI is the occurrence of aortic regurgitation (AR) after
valve implantation, which is mainly of periprosthetic origin
(5). Mild AR has been reported to occur in 50% of patients,
and higher degrees of AR, although less frequent, are clini-
cally relevant, and have been reported in frequencies between
7% and 20% (2,6). Recently, data from European registries
and from the only randomized TAVI trial have linked the
occurrence of post-TAVI AR with mortality (3,6–8).
In addition to the inherent limitations of the interventional
approach for valve therapy, compared with surgical aortic
valve replacement, that lead to the higher incidence of peri-
prosthetic AR, speciﬁc device-related factors may also have
an impact. However, the relationship between device type
and the occurrence of post-TAVI AR has not been
adequately analyzed. In the current study, we evaluated the
hemodynamic performance and the occurrence of AR after
TAVI with both prostheses from a large, 2-center experience.
Methods
Patient population. Between September 17, 2007, and
February 1, 2012, 394 consecutive patients underwent TAVI
using the Medtronic CoreValve (MCV) or the Edwards
Sapien XT valve (ESV) at 2 institutions with TAVI exper-
tise: Heart Center Segeberger Kliniken, Bad Segeberg,
Germany (n ¼ 202); and Heart Center Bad Krozingen, Bad
Krozingen, Germany (n ¼ 192). Both centers started their
TAVI program with the MCV; the ESV was introduced in
May 2010. The indication for TAVI was in concordance
with the consensus statement (5), and device selection since
May 2010 was determined by operator preference in
anatomically suitable patients. Baseline, procedural, and
follow-up parameters were prospectively recorded for all
patients and entered into a dedicated institutional database.
For the current analysis, patient-level data were pooled fromboth institutions, and the study cohort was retrospectively
divided according to the type of implanted prosthesis. In Bad
Krozingen, data on nontransfemoral cases were not pro-
spectively recorded and the imaging protocol was different.
Therefore, these patients have not been included. Data
collection was approved by the institutional review board of
both centers, and all patients provided written informed
consent for analysis of their anonymized data.
Pre-interventional assessment. Pre-interventional screening
included transthoracic echocardiography and transesophageal
echocardiography (TEE) to conﬁrm diagnosis, assess aortic
and aortic valve dimensions and morphology, and determine
the grade and distribution of calciﬁcation. Invasive cardiac
evaluation with coronary and supra-aortic angiography with
or without left ventriculography was performed in all pa-
tients. Multislice computed tomography (CT) was not
routinely performed, and selection of device size was largely
based on the aortic annulus
diameter estimated by TEE (9).
The angle between the axis of the
ﬁrst 4 cm of the ascending aorta
and the left ventricular outﬂow
tract (LVOT) axis (aorta-LVOT
angle) was assessed using left
ventriculography during prepa-
ration of the patients for the
procedure (10) and/or multislice
CT. The operative risk of the
patients was calculated by the
logistic EuroSCORE (European
System for Cardiac Operative
Risk Evaluation) (11). The de-
cision to perform TAVI was
made by a multidisciplinary team
consisting of an interventional
cardiologist, a conservative car-
diologist, a cardiac surgeon, and
an anesthesiologist, as suggested by current recommenda-
tions (5).
Device description. The MCV consists of porcine pericar-
dial tissue sewn to form a trileaﬂet valve mounted within a
self-expanding nitinol frame. The nitinol frame is around 50
mm in length and is hourglass-shaped. The prosthetic size is
determined by the external diameter of the ventricular end.
The 26-mm prosthesis is designed for patients with aortic
annular diameters of 20 to 23 mm, whereas the 29-mm
prosthesis is suitable for patients with 23 to 27 mm aortic
annuli. Recently, a 31-mm device has been introduced for
aortic annular diameters of 26 to 29 mm. The delivery
system of the MCV is currently 18-F. Details of the im-
plantation technique have been previously reported (2,12).
The ESV is a balloon-expandable valve with a cylindrical
cobalt-chromium stent into which 3 leaﬂets made of bovine
pericardium are mounted. During the study period, the valve
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286was available in 2 sizes: a 23-mm prosthesis for transverse
aortic annular diameters of 18 to 21.5 mm; and a 26-mm
prosthesis for aortic annular diameters of 21.5 to 25 mm.
Recently, a 29-mm prosthesis for aortic annular diameters of
25 to 27 mm has become available, but this size was not used
in the reported study. The current transfemoral delivery
system has 18-/19-F. Details of the implantation technique
have been previously reported (13).
Endpoints and deﬁnitions. The primary objective of this
analysis was to assess the incidence of more-than-mild AR
after the implantation of both TAVI devices. Further
outcome measures were device success and 30-day and
1-year mortality.
The degree of post-procedural AR was evaluated at the
end of the TAVI procedure after ﬁnal device deployment
and removal of the catheter and guidewire using both TTE
and angiography. Echocardiographic assessment was per-
formed with an integrative approach for semiquantitative
grading using a “jet anatomy” classiﬁcation, reporting on the
number, location, circumferential extent, and width of the
AR jet. The Valve Academic Research Consortium (VARC)
recommendations were adopted after their publication in
January 2011, and AR was qualitatively assessed by estimating
the proportion of the circumference of the valved stent
occupied by the jet: <10% was graded as mild, 10% to 20%
as moderate, and >20% as severe paravalvular AR (14,15).
Angiographic assessment of the severity of AR was performed
by visual estimation of the concentration of contrast medium
in the left ventricle, using the method of Sellers et al. (16).
Angiography was standardized regarding pigtail position
(well above the leaﬂets of the implanted prosthesis) as well as
contrast volume and ﬂow rate (35 ml at 18 ml/min). AR was
classiﬁed into the following grades: absent or trace (0); mild
(1/3); moderate (2/3); and severe (3/3); the latter comprised
grades 3 and 4 according to Sellers et al. (16). Evaluation was
initially performed by the treating physician. All angiographic
frames were further cross-checked between both centers by an
interventional cardiologist not involved in the TAVI proce-
dure. Discrepancies in the measured degree of post-TAVI
AR were resolved by consensus.
Device success was deﬁned as proposed by VARC as
a “technical” composite endpoint including: 1) successful
vascular access, delivery, and deployment of the device, and
successful retrieval of the delivery system; 2) correct position of
the device in the proper anatomical location; 3) intended
performance of the prosthetic heart valve (aortic valve area
>1.2 cm2 and mean aortic valve gradient <20 mm Hg or
peak velocity <3 m/s, without moderate or severe prosthetic
valve AR as assessed by echocardiography); and 4) only 1 valve
implanted in the proper anatomical location (14). Occurrence
of aortic annular rupture was considered a device failure.
Clinical follow-up was carried out during clinical visits
and/or through phone contact. The timing and frequency of
follow-up was determined by each center. Follow-up datawere prospectively gathered and were available in all patients
(100%). Death at any time during the follow-up period was
recorded, and mortality was deﬁned as all-cause death.
Statistical analysis. Statistical analysis was performed using
the Predictive Analytics Software (PASW statistics version
18, IBM, Armonk, New York). Continuous variables are
expressed as mean  SD or medians and interquartile ranges
and were analyzed with the Student t test or Mann-Whitney
test, as appropriate. Discrete variables are presented as
counts and percentages and were analyzed by the Pearson
chi-square or Fisher exact test, as appropriate. To avoid
potential bias caused by the nonrandomized allocation to 1
of the 2 devices, propensity score analyses were performed.
Variables selected for the propensity score were age, height,
weight, body surface area, serum creatinine, coronary artery
disease, previous percutaneous coronary intervention, pre-
vious bypass surgery, logistic EuroSCORE, pre-procedural
peak gradient, pre-procedural aortic valve area, annulus
diameter, diameter of ascending aorta, degree of leaﬂet
calciﬁcation, baseline AR, LV function, and aorta-LVOT
angle. The propensity score was estimated using a forward
stepwise multivariable logistic regression model (C-index ¼
0.76) and entered into the corresponding treatment effect
model as a covariate to adjust for baseline differences. Odds
ratio (OR) with 95% conﬁdence interval (CI) was deter-
mined. A receiver-operating characteristic curve was plotted
to determine a cutoff value for the aorta-LVOT angle
associated with the occurrence of more-than-mild AR with
both devices. The area under the curve (AUC) was deter-
mined, and a 95% CI for the AUC was found using the
bootstrap method. The maximum Youden index was used to
identify the cutoff point.
Kaplan-Meier survival plots were constructed from the
index procedure up to 1 year of follow-up and compared
with the log-rank test. Cox regression analysis was used to
assess independent predictors of survival at 1 year. The
variables included in the Cox model comprised age, sex,
body surface area, baseline New York Heart Association
functional class, peak gradient, aortic valve area, baseline
AR, baseline mitral regurgitation, pulmonary hypertension,
LV function, coronary artery disease, previous percutaneous
coronary intervention, previous bypass surgery, serum
creatinine, device type, and post-TAVI AR. A p value
<0.05 was deemed signiﬁcant. The authors had full access
to and take full responsibility for the integrity of the data. All
authors have read and agree to the paper as written.
Results
Baseline characteristics. A total of 394 consecutive patients
treated with TAVI at both institutions were included in this
analysis: 276 patients treated with MCV and 118 patients
treated with ESV. The procedure was mainly performed
through the transfemoral route, with only 2 patients in the
Table 1. Clinical Characteristics of the Study Population According to
Prosthesis Type
Medtronic
CoreValve
(n ¼ 276)
Edwards
Sapien XT
(n ¼ 118) p Value
Age, yrs 81.2  7.2 82.8  5.7 0.02
Male 125 (45.3) 29 (24.6) <0.001
Weight, kg 73.9  14.6 69.3  13.8 0.003
Height, cm 166.9  8.7 163.4  6.8 <0.001
BSA, m2 1.82  0.19 1.74  0.17 <0.001
Coronary artery disease 195 (70.1) 78 (66.1) 0.37
3-vessel disease 90 (32.6) 39 (33.1) 0.92
Previous CABG 54 (19.6) 15 (12.7) 0.10
Previous PCI 144 (52.2) 54 (45.8) 0.24
Baseline serum creatinine, mg/dl 1.19  0.78 1.15  0.54 0.60
Logistic EuroSCORE, % 22.27  13.39 20.61  13.93 0.27
NYHA functional class 0.02
I 1 (0.4) 0 (0)
II 17 (6.2) 15 (12.7)
III 210 (76.1) 93 (78.8)
IV 48 (17.4) 10 (8.5)
Values are mean  SD or n (%).
BSA ¼ body surface area; CABG ¼ coronary artery bypass graft; EuroSCORE = European
System for Cardiac Operative Risk Evaluation; NYHA ¼ New York Heart Association; PCI ¼
percutaneous coronary intervention.
Table 2. Echocardiographic Characteristics
Medtronic
CoreValve
(n ¼ 276)
Edwards
Sapien XT
(n ¼ 118) p Value
Aortic valve area, cm2 0.69  0.22 0.67  0.19 0.41
Indexed aortic valve area, cm2/m2 0.38  0.13 0.39  0.11 0.49
Mean aortic gradient, mm Hg 47.8  15.4 47.5  16.1 0.85
LV systolic function 0.01
Normal 151 (54.7) 79 (66.9)
Mildly impaired,
LVEF 45%–50%
41 (14.9) 21 (17.8)
Moderately impaired,
LVEF 35%–45%
42 (15.2) 11 (9.3)
Severely impaired, LVEF <35% 42 (15.2) 7 (5.9)
LV end-diastolic diameter, mm 49.4  7.8 47.8  5.8 0.11
LV end-systolic diameter, mm 33.9  8.9 32.2  7.3 0.15
Degree of leaﬂet calciﬁcation 0.12
Mild 5 (1.8) 0 (0)
Moderate 87 (31.5) 39 (33.1)
Severe 166 (66.1) 76 (64.4)
Aortic annulus
diameter, mm
23.4  2.2 22.6  1.5 <0.001
Pre-procedural AR 0.66
None 75 (27.2) 26 (22)
Mild 157 (56.9) 73 (61.9)
Moderate 34 (12.3) 16 (13.6)
Severe 10 (3.6) 3 (2.5)
Severe mitral regurgitation 11 (4.0) 2 (1.7) 0.36
Severe pulmonary hypertension* 37 (16.2) 14 (17.7) 0.58
Values are mean  SD or n (%). *Deﬁned as systolic pulmonary artery pressure >60 mm Hg.
AR ¼ aortic regurgitation; EF ¼ ejection fraction; LV ¼ left ventricle.
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287MCV group treated via the trans-subclavian approach, and 3
patients in the ESV group treated via the transapical
approach. Baseline clinical characteristics stratiﬁed by pros-
thesis type are shown in Table 1. Patients treated with the
MCV prosthesis were younger (81.2  7.2 years vs. 82.8 
5.7 years, p¼ 0.02), more commonly male (45.3% vs. 24.6%,
p< 0.001), had a larger body surface area (1.82 0.19 m2 vs.
1.74  0.17 m2, p < 0.001), and had a higher New York
Heart Association functional class. The logistic EuroSCORE
was comparable in both groups (22.27  13.39% vs. 20.61 
13.93% in the MCV and ESV group, respectively; p ¼ 0.27).
Pre-procedural echocardiographic details are shown in
Table 2. There were no signiﬁcant differences in the he-
modynamic severity of aortic stenosis between both groups,
and the degree of leaﬂet calciﬁcation was comparable.
However, the aortic annulus diameter as assessed by TEE
was slightly but signiﬁcantly larger in the MCV group (23.4
 2.2 mm vs. 22.6  1.5 mm, p < 0.001), as was the
proportion of patients with a left ventricular ejection fraction
<35% (15.2% vs. 5.9%, p ¼ 0.01). The aorta-LVOT angle
was signiﬁcantly larger in the ESV group (17.79  7.85 vs.
22.07  7.09, p < 0.001).
Procedural outcome. Details of the procedures and pro-
cedural outcome are shown in Table 3. The most common
valve used in the MCV group was the 29-mm valve
(63.8%), whereas the 26-mm valve was the most frequently
implanted ESV (78.8%). The mean implantation depth of
the MCV device was 8.3  3.5 mm to the noncoronary
cusp and 8.9  3.7 mm to the left coronary cusp. Balloonpost-dilation was performed more frequently in the MCV
group (18.1% vs. 3.4%, p < 0.001). The need for a second
valve and the occurrence of annulus rupture were low and
not different with both prostheses. The only case of
annular rupture with MCV occurred in a 91-year-old
woman with an aortic annulus diameter of 20 mm and
moderate leaﬂet calciﬁcation. Balloon valvuloplasty was
performed with an 18-  40-mm balloon, but the balloon
ruptured after full inﬂation. Immediately after implantation
of a 26-mm valve, the patient developed intractable shock,
and annulus rupture was diagnosed (no post-dilation was
performed). Pericardiocentesis was performed with aspira-
tion of 300 ml of blood, but this did not improve the
condition, and the patient did not survive. Immediate
procedural mortality occurred in 3 patients overall (1.1%)
in the MCV group and 2 patients (1.7%) in the ESV
group (p ¼ 0.64).
Post-TAVI AR was assessed in 391 patients, with no AR
evaluation in the 3 patients with a ruptured aortic annulus.
The occurrence of post-TAVI AR stratiﬁed by device type
is shown in Table 4; AR was paravalvular in origin in
all observed cases. The occurrence of more-than-mild
Table 3. Procedural Details of 394 Patients Undergoing TAVI
Stratiﬁed According to Prosthesis Type
Medtronic
CoreValve
(n ¼ 276)
Edwards
Sapien XT
(n ¼ 118) p Value
Valve size, mm <0.001
23 d 25 (21.2)
26 96 (34.8) 93 (78.8)
29 176 (63.8) d
31 4 (1.4) d
Cover index, %* 16.31  5.96 11.01  4.62 <0.001
Need for balloon post-dilation 50 (18.1) 4 (3.4) <0.001
Annulus rupture 1 (0.4) 2 (1.7) 0.21
Implantation of 2 valves 3 (1.1) 1 (0.8) 1.0
Values are n (%) or mean  SD. *Cover index ¼ 100  (prosthesis diameter – transesophageal
echocardiography annulus diameter)/prosthesis diameter.
TAVI ¼ transcatheter aortic valve implantation.
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288post-TAVI AR as assessed by transthoracic echocardiogra-
phy (the primary endpoint) was higher in the MCV group
(12.7% vs. 2.6%, p ¼ 0.002). This difference remained
signiﬁcant after propensity adjustment, with an adjusted OR
for the MCV prosthesis of 4.59 (95% CI: 1.03 to 20.44,
p ¼ 0.04). The occurrence of any degree of AR was also
higher in the MCV group (71.6% vs. 56.9%, p ¼ 0.004).
Similar results were seen when AR was assessed by supra-
aortic angiography (more-than-mild AR in 32.5% vs. 18.1%,
p ¼ 0.004; any AR in 82.8% vs. 58.6%, p < 0.001, in the
MCV and ESV group, respectively). When the analysis was
restricted to the period during which both devices were
simultaneously implanted (May 2010 to February 2012),
the incidence of more-than-mild AR was still higher withTable 4. Residual AR and Device Success in the Study Population
Medtronic
CoreValve
(n ¼ 276)
Edwards
Sapien XT
(n ¼ 118) p Value
Final aortic regurgitation, echo 0.002
None/trace 78 (28.4) 50 (43.1)
Mild 162 (58.9) 63 (54.3)
Moderate 31 (11.3) 2 (1.7)
Severe 4 (1.5) 1 (0.9)
Final aortic regurgitation, angio <0.001
None/trace 47 (17.2) 48 (41.4)
Mild 138 (50.4) 47 (40.5)
Moderate 66 (24.1) 16 (13.8)
Severe 23 (8.4) 5 (4.3)
Aortic regurgitation index* 24.8  9.5 26.0  8.5 0.33
Device success 239 (86.6) 113 (95.8) 0.007
Values are n (%) or mean  SD. *Calculated as: ([diastolic blood pressure – left ventricular
end-diastolic pressure]/systolic blood pressure)  100 (22) and retrospectively determined in
244 CoreValve and 77 Edwards Sapien XT patients.
angio ¼ angiography; AR ¼ aortic regurgitation; echo ¼ echocardiography.MCV than with ESV (12 of 127 [9.4%] vs. 3 of 116 [2.6%],
p ¼ 0.03). A similar trend was observed in patients treated
with a 26-mm device (more-than-mild AR in 10.5% vs.
3.3%, p ¼ 0.05).
Device success according to the VARC deﬁnition was
mainly inﬂuenced by the occurrence of post-TAVI AR
and was consequently higher with ESV than with MCV
(95.8% vs. 86.6%, p ¼ 0.007) (Table 5). This remained
higher but just failed to reach statistical signiﬁcance in the
propensity-adjusted analysis (adjusted OR: 0.34, 95% CI:
0.11 to 1.03, p ¼ 0.06).
Relationship between aorta-LVOT angle and post-TAVI AR.
The aorta-LVOT angle was larger in patients with mod-
erate/severe AR than in those with no/mild AR in the MCV
group (20.3  8.4 vs. 17.4  7.7, p ¼ 0.05) but not in the
ESV group (19.0  16.9 vs. 22.2  6.9, p ¼ 0.53). Using
receiver-operating characteristic curve analysis, the rela-
tionship between the angle and the occurrence of more-
than-mild AR was strong with MCV (AUC: 0.792, 95%
CI: 0.728 to 0.857) and not with ESV (AUC: 0.531, 95%
CI: 0.389 to 0.673). Using a cutoff value of 18, the
sensitivity and speciﬁcity of predicting more-than-mild AR
in the MCV group were 0.81 and 0.72, respectively.
Short-term and 1-year survival. At a mean follow-up of 9.6
 3.6 months, a total of 55 patients (14.0%) had died, 17
patients (4.3%) died within 30 days after TAVI, and 38
patients (9.7%) died during the follow-up period. At 1 year,
survival was not signiﬁcantly different between both valve
types (88.2% vs. 83.8% in the ESV and MCV group,
respectively, log-rank p ¼ 0.42) (Fig. 1). Survival was worse
in patients with more-than-mild post-TAVI AR as assessed
by echocardiography (69.8% vs. 87.4%, log-rank p ¼ 0.004)
as well as by angiography (75.3% vs. 89.7%, log-rank p <
0.001) (Fig. 2). Using Cox regression analysis, more-
than-mild AR was independently associated with mortality
at 1 year (adjusted hazard ratio: 2.18, 95% CI: 1.02 to 4.67
for echocardiography; adjusted hazard ratio: 2.46, 95%
CI: 1.32 to 4.61 for angiography) (Fig. 3). Survival wasTable 5. Causes of Device Failure in the Study Population
Medtronic
CoreValve
(n ¼ 276)
Edwards
Sapien XT
(n ¼ 118)
Unsuccessful vascular access, delivery, and
deployment of the device, and retrieval
of the delivery system
0 0
Incorrect position of the device in the
proper anatomical location
3 (1.1) 0
Inadequate performance, moderate or severe
prosthetic valve AR
35 (12.7) 3 (2.6)
>1 valve implanted in the proper
anatomical location
3 (1.1) 1 (0.8)
Annulus rupture 1 (0.4) 2 (1.7)
Values are n (%).
AR ¼ aortic regurgitation.
Figure 1. 1-Year Survival According to Device Type
Kaplan-Meier survival curves up to 1 year after transcatheter aortic valve
implantation for patients treated with CoreValve versus Edwards Sapien XT
valves.
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289signiﬁcantly lower in patients with initial device failure than
in those with device success (65.6% vs. 87.4%, log-rank
p < 0.001) (Fig. 4).
Discussion
In this study of 394 TAVI patients treated with the MCV or
ESV prosthesis predominantly through the transfemoral
route, more-than mild AR after TAVI quantiﬁed byFigure 2. Relation of More-Than-Mild AR to Survival After TAVI
Kaplan-Meier survival curves up to 1 year after transcatheter aortic valve implantation
AR as assessed by transthoracic echocardiography (A) and angiography (B).echocardiography was signiﬁcantly higher with MCV by
both unadjusted and propensity-adjusted analysis. Conse-
quently, device success as deﬁned by VARC was higher with
the ESV. These differences were consistent when AR was
assessed by angiography. Both more-than-mild AR after
TAVI and device failure were related to a signiﬁcant increase
in mortality within 1 year after TAVI.
The MCV and ESV are the most commonly used
transfemoral devices in Europe. The development of AR
following TAVI is multifactorial and depends on several
factors related to the aortic root anatomy and its relation to
the implanted prosthesis. These include the shape and size
of the annulus, degree of annular and leaﬂet calciﬁcation,
prosthesis/annulus discongruence, and LVOT anatomy
(10,17,18). In addition, speciﬁc device-related factors may
also have an impact. Despite the obvious differences between
both technologies (balloon- vs. self-expandable implanta-
tion, cobalt chromium vs. nitinol stent frame, bovine vs.
porcine valve leaﬂets, and so on), and the potential impact of
these differences on device performance and residual AR,
comparative data about their hemodynamic performance are
scarce. In the German TAVI registry, the MCV prosthesis,
compared with ESV, was associated with higher odds for
more-than-mild AR (adjusted OR: 1.58, 95% CI: 0.73 to
3.40), but this was not statistically signiﬁcant (6). Impor-
tantly, the MCV device was the one predominantly used in
this study (84% vs. 16%), and the ESV used was an early
generation device with a stainless steel frame and a slightly
different implantation technique (6). More recently, higher
frequencies of post-procedural AR were reported for MCV(TAVI) in patients with no/mild aortic regurgitation (AR) versus moderate/severe
Figure 3. Adjusted Survival Curves
Adjusted survival curves in patients with no/mild aortic regurgitation (AR) versus moderate/severe AR as assessed by transthoracic echocardiography (A) and
supra-aortic angiography (B).
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290versus ESV in a well-balanced cohort from the U.K. TAVI
(United Kingdom Transcatheter Aortic Valve Implantation)
registry (452 MCV patients vs. 410 ESV patients, moderate
or severe AR 17.3% vs. 9.6%, respectively; p ¼ 0.001) (3)
and in the large FRANCE 2 (French Transcatheter Aortic
Valve Intervention Registry) (21.5% vs. 13.9%) (19). On the
other hand, in a recently published multicenter collaborative
study (the PRAGMATIC PLUS [Pooled-Rotterdam-
Milano-Toulouse In Collaboration Plus] initiative), the
incidence of more-than-mild AR was extremely low and
comparable between both devices (2.0% with MCV and
1.8% with ESV) (20). In all of these studies, AR was assessedFigure 4. Relation of Initial Device Success to Survival After TAVI
Kaplan-Meier survival curves up to 1 year in patients with and without
device success as deﬁned by the Valve Academic Research Consortium.
TAVI ¼ transcatheter aortic valve implantation.by either angiography (German and U.K. registries) or
echocardiography (FRANCE 2 and PRAGMATIC PLUS).
The current analysis, although retrospective, is the ﬁrst attempt
to formally compare the contemporary self- and balloon-
expanding technologies with respect to post-procedural AR
assessed by both echocardiography and angiography, in addi-
tion to device success deﬁned according to VARC. Using
both techniques, all degrees of residual post-TAVI AR were
signiﬁcantly lower with the balloon-expandable device, even
after statistical adjustment. Consequently, device success was
higher with the balloon-expandable device, but this was not
statistically signiﬁcant in the propensity-score analysis.
Identifying and accurately characterizing paravalvular
leaks after TAVI is challenging. The shadowing and re-
verberations of the valvular stent frame as well as the ec-
centricity and irregularity of the jets make accurate
localization and quantiﬁcation of paravalvular regurgitation
difﬁcult. Supra-aortic angiography is an established tool for
qualitative and semiquantitative assessment of AR, is readily
available during the TAVI procedure, and can be quickly
performed to provide essential information and initiate
further management. Its downside is that it depends on
subjective interpretation of unidimensional images, and it is
difﬁcult to determine the contribution of paravalvular and
central AR (21). Echocardiography can identify the presence
and location of AR after TAVI, but evaluation of severity of
paravalvular regurgitation remains complex and challenging,
and the suggested VARC criteria have not been validated in
this setting. The different proportion of patients that were
categorized as having more-than-mild AR by echocardiog-
raphy compared with angiography in our cohort highlights
the difﬁculty of quantifying paravalvular AR in these pa-
tients. Hemodynamic data obtained immediately after TAVI
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291that include left ventricular end-diastolic pressure and aortic
diastolic pressure can provide additional information about
grading the severity of AR, and a recently described AR
index has been shown to be of prognostic value (22). In our
series, the decision for further interventions after TAVI was
mainly driven by the angiographic and echocardiographic
ﬁndings, but hemodynamic data were also considered in
borderline cases. Importantly, and despite the prognostic
utility demonstrated by the AR index, it remains a variable
parameter affected by a number of hemodynamic measures
such as heart rate, left ventricular end-diastolic pressure, and
aortic stiffness, and thus results may not go hand-in-hand
with the imaging evaluation of AR.
The observed differences in AR between both devices may
have various explanations. First, proper device positioning is
an important factor related to the occurrence of AR in both
devices, and deep implantation would result in severe AR, as
the covered skirt would be situated below the native annulus,
allowing blood to regurgitate through the holes of the un-
covered portion of the stent frame. Nevertheless, MCV is a
long device and allows for a wide range of implant depths.
Signiﬁcant paravalvular AR due to malposition of the valve
could be more evident, as the valve is more forgiving and will
function normally without embolizing under less precise
deployment (23). On the other hand, ESV may carry less
risk of signiﬁcant paravalvular AR due to malposition, as
most valves in this scenario will embolize (23). Although the
8-mm device depth in our MCV cohort lies within the
previously reported 5- to 10-mm range believed to minimize
the risk of more-than-mild AR (10,24), current practice
trends favor even higher implantation of MCV, which could
further decrease AR (25). Second, the hemodynamic per-
formance of the longer MCV prosthesis within the aortic
annulus depends on the anatomical relationship (angle) be-
tween the ascending aorta and the LVOT, which may affect
the ability of the nitinol-stent to provide adequate radial
force (10), whereas the shorter ESV is probably less inﬂu-
enced by this anatomical variable. Supporting this hypo-
thetical explanation, the aorta-LVOT angle in our study was
larger in patients with moderate/severe AR than in those
with no/mild AR in the MCV and not in the ESV group.
Finally, a certain degree of prosthesis oversizing (typically 5%
to 30%) is needed with both devices to ensure an adequate
adaptation of the prosthesis to the aortic annulus. The aim of
oversizing is to create enough radial force between the
prosthetic valve and aortic valvular complex to ensure
adequate anchoring and sealing (26). It is not known
whether the degree of oversizing should differ with balloon-
expandable versus self-expandable devices, but the latter
seem to have less radial force. In the current analysis, the
degree of oversizing as reﬂected by the cover index (18)
was signiﬁcantly higher with MCV, making it unlikely
that device undersizing has contributed to the observed
difference in AR. Nevertheless, sizing was mainly based on2-dimensional TEE measurements, and recent data have
suggested that CT-derived 3-dimensional annular mea-
surements are predictive of moderate or severe AR follow-
ing TAVI (27,28). Whether device oversizing based on
3-dimensional imaging could alter the observed differences
in AR with both devices is uncertain.
Recent analyses suggested the importance of post-
procedural AR for short- and long-term outcomes after
TAVI (3,6–8). In our analysis, more-than-mild AR was
strongly associated with mortality at 1 year, and this associ-
ation was consistent and independent of the method of AR
assessment. In addition, device success was strongly associ-
ated with short- and intermediate-term mortality, indicating
its clinical relevance as a composite endpoint for future
clinical trials comparing different TAVI devices. Neverthe-
less, we did not observe a signiﬁcant difference in mortality
between both devices. This could be explained by the
moderate sample size of this study, the small differences in
mostly severe AR, and the ongoing “background” events of
death that occur in patients in their eighties. Notably, and
despite the observed differences in AR between both devices
in the U.K. TAVI and FRANCE 2 registries, no difference
in mortality has been observed in both studies (3,19).
Whether the observed differences in AR represent a
clinically-relevant beneﬁt for 1 device over the other is still
not known and will only be determined through randomized
controlled studies.
Study limitations. Due to the nonrandomized and retro-
spective nature of the study, the ﬁndings are subject to se-
lection bias and confounding, and the numbers in both
groups are not balanced. Therefore, propensity score analyses
were performed. However, hidden bias may remain due to
the inﬂuence of unmeasured confounders (e.g., pattern and
location of calciﬁcation, operator preference, and learning
curve). The potential shortcomings of relying on 2-dimen-
sional measurements of the aortic annulus for sizing and the
lack of precise anatomic evaluation of the device landing zone
(especially annular calciﬁcation) may have affected the
occurrence of AR with both prostheses. A randomized study
is needed to conﬁrm or dispute the results of this analysis,
and this trial is currently ongoing (The CHOICE trial [A
Comparison of Transcatheter Heart Valves in High Risk
Patients With Severe Aortic Stenosis]; NCT01645202).
Almost all reported procedures were performed trans-
femorally. Recent data have suggested a lower incidence of
post-TAVI AR with the nontransfemoral approach (19), but
this remains to be conﬁrmed. Finally, the Cox regression
survival analysis could be overﬁtted by traditional standards.
Conclusions
In our 2-center experience of almost 400 TAVI patients, the
MCV was more prone to more-than-mild post-implanta-
tion AR than the ESV prosthesis was. This ﬁnding deserves
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292consideration, as more-than-mild AR was associated with
higher mortality at 1 year.Acknowledgment
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